The stock of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) has increased by 4.91 when compared to last closing price of 2.65.Despite this, the company has seen a gain of 13.01% in its stock price over the last five trading days. globenewswire.com reported 2025-05-13 that Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. “As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo.
Is It Worth Investing in Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Right Now?
Additionally, the 36-month beta value for MREO is 0.36. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MREO is 143.85M and currently, short sellers hold a 5.86% ratio of that float. The average trading volume of MREO on June 12, 2025 was 1.38M shares.
MREO’s Market Performance
MREO stock saw an increase of 13.01% in the past week, with a monthly gain of 19.83% and a quarterly increase of 11.20%. The volatility ratio for the week is 6.15%, and the volatility levels for the last 30 days are 5.27% for Mereo Biopharma Group Plc ADR (MREO). The simple moving average for the past 20 days is 15.40% for MREO’s stock, with a -14.42% simple moving average for the past 200 days.
Analysts’ Opinion of MREO
Many brokerage firms have already submitted their reports for MREO stocks, with JP Morgan repeating the rating for MREO by listing it as a “Overweight.” The predicted price for MREO in the upcoming period, according to JP Morgan is $7 based on the research report published on March 27, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see MREO reach a price target of $7. The rating they have provided for MREO stocks is “Buy” according to the report published on December 06th, 2024.
Robert W. Baird gave a rating of “Outperform” to MREO, setting the target price at $8 in the report published on June 13th of the previous year.
MREO Trading at 18.80% from the 50-Day Moving Average
After a stumble in the market that brought MREO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.62% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MREO starting from Scots-Knight Denise, who sale 60,046 shares at the price of $4.22 back on Sep 13 ’24. After this action, Scots-Knight Denise now owns 808,921 shares of Mereo Biopharma Group Plc ADR, valued at $253,454 using the latest closing price.
Scots-Knight Denise, the Chief Executive Officer of Mereo Biopharma Group Plc ADR, sale 28,611 shares at $4.47 during a trade that took place back on Sep 12 ’24, which means that Scots-Knight Denise is holding 868,967 shares at $127,968 based on the most recent closing price.
Stock Fundamentals for MREO
The total capital return value is set at -0.8. Equity return is now at value -92.00, with -76.20 for asset returns.
Based on Mereo Biopharma Group Plc ADR (MREO), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -44.43. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -55.36.
Currently, EBITDA for the company is -47.36 million with net debt to EBITDA at 1.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.92.
Conclusion
In conclusion, Mereo Biopharma Group Plc ADR (MREO) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
